Liat Zalts - Pluri Chief Treasurer
| PLUR Stock | USD 4.46 0.12 2.62% |
Executive
Liat Zalts is Chief Treasurer of Pluri Inc
| Age | 40 |
| Address | Building No. 5, Haifa, Israel, 3508409 |
| Phone | 972 74 710 8600 |
| Web | https://www.pluri-biotech.com |
Liat Zalts Latest Insider Activity
Tracking and analyzing the buying and selling activities of Liat Zalts against Pluri stock is an integral part of due diligence when investing in Pluri. Liat Zalts insider activity provides valuable insight into whether Pluri is net buyers or sellers over its current business cycle. Note, Pluri insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pluri'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Liat Zalts over two months ago Insider Trading |
Pluri Management Efficiency
The company has return on total asset (ROA) of (0.3067) % which means that it has lost $0.3067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0607) %, meaning that it created substantial loss on money invested by shareholders. Pluri's management efficiency ratios could be used to measure how well Pluri manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/24/2024, Return On Tangible Assets is likely to drop to -0.55. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Pluri's Non Currrent Assets Other are relatively stable compared to the past year. As of 12/24/2024, Debt To Assets is likely to grow to 0.65, while Non Current Assets Total are likely to drop slightly above 7.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MPH MD | Karyopharm Therapeutics | N/A | |
| Bahram Valamehr | Fate Therapeutics | 47 | |
| Pia Eaves | Arcus Biosciences | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Jerome Bressi | Fate Therapeutics | N/A | |
| Yvonne Gehring | Arcus Biosciences | N/A | |
| Andrew Henry | Fate Therapeutics | 60 | |
| Eric Hoefer | Arcus Biosciences | N/A | |
| Cameron Peters | Karyopharm Therapeutics | 64 | |
| Stuart Poulton | Karyopharm Therapeutics | N/A | |
| Stephen Young | Arcus Biosciences | 55 | |
| Sohanya MBA | Karyopharm Therapeutics | 41 | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Jennifer MBA | Arcus Biosciences | 53 | |
| Jim MBA | Fate Therapeutics | N/A | |
| Elhan CFA | Karyopharm Therapeutics | N/A | |
| Brian Austad | Karyopharm Therapeutics | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Timothy MBA | Caribou Biosciences | 55 | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Jennifer Jarrett | Arcus Biosciences | 50 | |
Management Performance
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.31 |
Pluri Inc Leadership Team
Elected by the shareholders, the Pluri's board of directors comprises two types of representatives: Pluri inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pluri. The board's role is to monitor Pluri's management team and ensure that shareholders' interests are well served. Pluri's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pluri's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lior Raviv, Chief Officer | ||
| Nimrod Zvi, Chief Officer | ||
| John Dvor, EVP America | ||
| Liat Zalts, Chief Treasurer | ||
| Efrat LivneHadass, Vice Resources | ||
| Yaacov Yanay, CEO President | ||
| Orly Amiran, Chief Officer | ||
| Arthur Machlenkin, Chief Officer | ||
| Chen FrancoYehuda, Treasurer CFO | ||
| Nitsan MD, Chief Officer | ||
| Efrat Kaduri, Chief Pharma |
Pluri Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pluri a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (62.85) % | ||||
| Current Valuation | 32.01 M | ||||
| Shares Outstanding | 5.56 M | ||||
| Shares Owned By Insiders | 23.52 % | ||||
| Shares Owned By Institutions | 9.65 % | ||||
| Number Of Shares Shorted | 8.54 K | ||||
| Price To Book | 306.56 X | ||||
| Price To Sales | 82.19 X |
Pair Trading with Pluri
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pluri position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pluri will appreciate offsetting losses from the drop in the long position's value.Moving against Pluri Stock
The ability to find closely correlated positions to Pluri could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pluri when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pluri - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pluri Inc to buy it.
The correlation of Pluri is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pluri moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pluri Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pluri can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Pluri Stock Analysis
When running Pluri's price analysis, check to measure Pluri's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluri is operating at the current time. Most of Pluri's value examination focuses on studying past and present price action to predict the probability of Pluri's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluri's price. Additionally, you may evaluate how the addition of Pluri to your portfolios can decrease your overall portfolio volatility.